(3S,5S)-4-(4-bromo-3-fluorobenzyl)-3,5-dimethylmorpholine | 1252575-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3S,5S)-4-(4-bromo-3-fluorobenzyl)-3,5-dimethylmorpholine
• 英文别名: (3S,5S)-4-[(4-bromo-3-fluorophenyl)methyl]-3,5-dimethylmorpholine
• CAS: 1252575-73-7
• 化学式: C₁₃H₁₇BrFNO
• 分子量: 302.186
• InChiKey: UKXZLWREBIGTJT-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3S,5S-二甲基吗啉 、 4-溴-3-氟苯甲醛 在 氨 、 三乙酰氧基硼氢化钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以30%的产率得到(3S,5S)-4-(4-bromo-3-fluorobenzyl)-3,5-dimethylmorpholine
  参考文献：
  名称：

  Imidazole Substituted Pyrimidines

  摘要：

  式（I）的化合物，其中R1为氢或氟；R2和R3分别选择自氢或甲基，或其药用可接受的盐；含有该化合物的药物配方；该化合物在治疗中的使用；用于治疗与糖原合酶激酶-3相关疾病的条件，如阿尔茨海默病，以及治疗上述疾病的方法，包括向需要该治疗的受试者施用该化合物的治疗有效量。

  公开号：

  US20100267723A1

文献信息

• Imidazole substituted pyrimidines
  申请人：AstraZeneca AB

  公开号：US08178529B2

  公开（公告）日：2012-05-15

  Imidazole substituted pyrimidines and pharmaceutically acceptable salts thereof; pharmaceutical formulations containing such pyrimidines; the use of such compounds in therapy; the use of such compounds for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as methods of treatment of such disorders comprising administering to subjects in need of such treatment therapeutically effective amounts of such compounds.

  咪唑取代嘧啶及其药学上可接受的盐；含有这种嘧啶的制药配方；使用这种化合物进行治疗；使用这种化合物治疗与糖原合成酶激酶-3相关疾病有关的病症，例如阿尔茨海默病，以及治疗这种疾病的方法，包括向需要这种治疗的患者施用这种化合物的治疗有效量。
• Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease
  申请人：Burrows Jeremy Nicholas

  公开号：US20120077813A1

  公开（公告）日：2012-03-29

  The present invention relates to a new compound of formula (I) wherein R 1 is hydrogen or fluoro; R 2 and R 3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.

  本发明涉及一种新的化合物，其化学式为（I），其中R1是氢或氟；R2和R3分别选择氢或甲基；或其药学上可接受的盐，含有该化合物的制药配方，以及将该活性化合物用于治疗的用途，用于治疗与糖原合成酶激酶-3相关疾病有关的疾病，例如阿尔茨海默病，以及治疗该疾病的方法，包括向需要此类治疗的哺乳动物，包括人类，给予该化合物的治疗有效量。
• IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE
  申请人：AstraZeneca AB

  公开号：EP2419425A1

  公开（公告）日：2012-02-22
• US8178529B2
  申请人：——

  公开号：US8178529B2

  公开（公告）日：2012-05-15
• [EN] IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE<br/>[FR] PYRIMIDINES SUBSTITUÉES PAR IMIDAZOLE UTILES DANS LE TRAITEMENT DE TROUBLES LIÉS À LA GLYCOGÈNE SYNTHASE KINASE 3, TELS QUE LA MALADIE D'ALZHEIMER
  申请人：ASTRAZENECA AB

  公开号：WO2010120237A1

  公开（公告）日：2010-10-21

  The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.